Kornimate/medical-research-clean huggingface dataset:
pruritus and pemphigoid in nursing home patients

Conditions: Pemphigoid; Pruritus

Summary: the primary objective of this observational study is to describe the prevalence of pruritus and pemphigoid in nursing home patients. secondary outcomes are the relationships of demographic factors and medical risk factors with pemphigoid, including dementia and neuropsychiatric symptoms, medication use and karnofsky score.

pruritus or itch is the most common skin symptom in elderly patients and is estimated to affect more than 30% of nursing home patients. clinical and experimental evidence suggests pruritus in elderly patients may be linked to pemphigoid. pemphigoid is the most common autoimmune skin blistering diseases and mainly affects the elderly. it is successfully treatable with systemic therapy. however, pemphigoid is often missed as a cause of pruritus in elderly patients (nonbullous cutaneous pemphigoid). although nursing home patients and patients with dementia in particular have the highest risk for development of pemphigoid, no study has been performed in this population so far. including serological screening for pemphigoid in the diagnostic evaluation of chronic pruritus in nursing home patients may lead to the diagnosis of pemphigoid. furthermore, chronic itch may be an unrecognized cause of neuropsychiatric symptoms in nursing home patients with dementia.

Eligibility criteria:
inclusion criteria: * inpatient of a nursing home * age 65 years or above * subject or their official representatives have signed informed consent exclusion criteria: * age below 65 years * subjects who do not have signed informed consent * receiving treatment with any systemic immunosuppressive agents * terminally ill patients with a life expectancy of less than 4 weeks

Keywords: pemphigoid bullous pemphigoid pruritus senile pruritus neuropsychiatric symptoms
establishing a sonographic based algorithm to verify pancreatic stent position placed to prevent post-ercp pancreatitis before endoscopic removal

Conditions: Post-ERCP Acute Pancreatitis; Pancreatic Stent; Ultrasound; X-rays

Summary: the present study is a prospective, single-center study. a total of 88 patients, who had placed a pancreatic stent for preventing post-ercp pancreatitis, will be included in the study. aim of the study is to establish a new algorithm based on a sonographic approach to remove the placed pancreatic stents. another aim is to compare high-end sonographic devices with devices of medium price scale one's used on the ward. on the day of removal of the pancreatic stent, all patients receive a sonography by an experienced investigator on the ward and by another, uninformed investigator with a high-end device. if a pancreatic stent is visualized in the pancreatic duct, the patient will have an esophagogastroduodenoscopy to remove the pancreatic stent. if sonography cannot find a pancreatic stent in the pancreatic duct an x-ray will be performed as suggested by the european and international guidelines. if the pancreatic stent spontaneously dislocated into the small bowel tract according to x-ray, no further investigation will be performed. if a stent is visulized in situ by x-ray, it will be removed by endoscopyl. statistical analysis will be done in cooperation with the statistical biomedical institute oft he university hospital in frankfurt.


Eligibility criteria:
inclusion criteria: * placement of prophylactic pancreatic stent to prevent post-ercp-pancreatitis * age of at least 18 years * written informed consent exclusion criteria: * diseases that prevent sonography, x-ray or esophagogastroduodenoscopy * no given consent * other indication for pancreatic stenting

Keywords: post-ercp acute pancreatitis pancreatic stent ultrasound x-rays endoscopy esophagogastroduodenoscopy
calcaneal neck lengthening osteotomy with artificial bone graft

Conditions: Flatfoot

Summary: in this foot deformity (plano valgus) surgery may be indicated. the deformity is corrected with an osteotomy at the heelbone. in most cases bone graft material has to be obtained from the iliac crest to support the osteotomy. in the planned study a group of children will be operated with an artificial bone graft material and thus avoiding the need harvesting of bone graft at the iliac crest.

planovalgus or flatfoot deformity is observed in children with different neuromuscular disorders and is associated with pain and gait disorders due to non-reducible talonavicular joint subluxation. surgical treatment is aimed at correcting foot malalignement and achieving sufficient plantar flexion in the ankle joint. with a calcaneal lengthening osteotomy procedure the planovalgus deformity can be corrected but it requires the use of graft material to be inserted as a bone wedge at the osteotomy site. in this way the talonavicular joint is indirectly reduced. obtaining autograft material from the iliac crest in growing children carries a risk of growth arrest and iliac wing deformity which has led to widespread use of allograft bone when performing the operation. new materials are being developed as substitutes for bone graft material with biphasic calcium phosphate ceramic (bcp) being the most commonly used. bcp is a mixture of porous hydroxyapatite (ha) and β-tricalcium phosphate (β -tcp). calcium phosphate ceramics have excellent biocompatibility and are thought to be able to facilitate and guide new bone growth. this has been demonstrated in experimental studies. in retrospective clinical studies on patients having filled large bone defects with hydroxyapatite graft material radiological healing is seen at follow ups after average 7.9 years. it has also previously been demonstrated that bcp can be used as artificial bone graft in osteotomies with a good result and complete healing of the osteotomi.

Eligibility criteria:
inclusion criteria: * flatfoot condition needing surgery exclusion criteria: * traumatic conditions
drug coated balloons vs plain balloons for the management of dysfunctional dialysis fistula

Conditions: Dysfunctional Dialysis Arteriovenous Fistula

Summary: compare the effectiveness of drug-coated balloons to plain balloon angioplasty in reducing stenosis rates in dialysis arteriovenous fistulas (avfs).

objectives of the study: hypothesis: drug-coated balloons improve functional and patency outcomes of failing/dysfunctional hemodialysis fistulas compared to plain uncoated balloons aim of the study: compare the effectiveness of drug-coated balloons to plain balloon angioplasty in reducing stenosis rates in dialysis avfs. specific objectives: primary functional endpoint: access circuit patency based on functional criteria at 12 month. primary safety endpoint: peri procedural complication rate secondary endpoints: * technical success (\<30% residual stenosis without postdilation) * access circuit dysfunction free survival (time to event) based on functional criteria * target lesion restenosis free survival (time to event) (in case of new lesion causes circuit dysfunction)

Eligibility criteria:
inclusion criteria: * inclusion criteria * \>18 year old * dysfunctional dialysis fistula * radiocephalic * brachiocephalic * brachiobasilic clinical criteria for diagnosis of dysfunctional fistula: * swelling of the fistula limb * prolonged bleeding after withdrawing access needles * abnormal pulsations or weak thrill. * functional criteria for the diagnosis of dysfunctional criteria: * arteriovenous fistula is unable to deliver dialysis blood flow (qb) of equal to or more than 300 ml/min and/or access recirculation of more than 10% on at least two occasions, * a rising trend of venous pressure or excessive negative arterial pressure, and/or unable to deliver a kt/v of 1.2 or more. * non-thrombosed exclusion criteria: * dysfunctional arteriovenous (av) grafts * thrombosed fistulas * intra-stent stenosis * stenoses not responding to balloon angioplasty and requiring stenting. * stenosis less than 50% * surgical intervention that excludes the treatment segment from the access circuit * systemic or local (to the fistula) infection treated for less than 10 days prior to the study procedure * location of isolated stenosis central to the thoracic inlet. * women who are breastfeeding, pregnant or are intending to become pregnant * known hypersensitivity or contraindication to contrast medium which cannot be adequately premeditated. * sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel
a retrospective epidemiological study on pneumococcal infection in children in ministry of health hospital at ehsa region in the eastern province

Conditions: Pneumococcal Infection

Summary: the purpose of this study is to establish retrospectively the incidence rates of invasive pneumococcal disease in children aged less than 5 years. the investigators allocate the el hasa region for the study because it has higher incidence of sickle cell anemia. the study will include data from 2003 to 2007(before introduction of the vaccine) and then for 2008 and 2009 (after introduction of the vaccine).

data will be collected from patents files or records for 5 years before the introduction of the vaccine and for 2 years after the introduction of the vaccine. we assigned 4 doctors in each hospital to carry and supervise the work.

Eligibility criteria:
inclusion criteria: * invasive pneumococcal disease * children under 5 years * children lived in elhasa region exclusion criteria: * children above 5 years * no invasive pneumococcal disease

Keywords: risk factors case fatality disease burden resistance benefits of pneumococcal vaccination
comparison of ventilation with bag-valve-mask, laryngeal tube s-d and laryngeal mask airway supreme

Conditions: Cardiopulmonary Arrest

Summary: inexperienced rescuers may encounter severe problems in an unconscious patient in opening and maintaining an upper airway patent. gaining evidence which ventilation technique may be most efficient and safe is of utmost importance to potentially improve outcome during cardiopulmonary resuscitation.

during cardiopulmonary resuscitation (cpr) ventilation has to be efficient to provide oxygen to the body and safe to avoid potentially fatal regurgitation and aspiration pneumonia and excessive stomach inflation. basically trained rescuers have severe problems to ventilate a patient during cardiopulmonary resuscitation. this study intends to compare three commonly employed ventilation techniques. first, the traditionally bag-valve mask ventilation is commonly taught during cpr course, despite recent evidence suggesting low efficiency rates. second, the laryngeal mask and the laryngeal tube supraglottic airways have shown high efficiency and safety in previous studies in the hand of experienced clinicians. until now it is unclear if basically trained rescuers are better in ventilation with bag valve mask ventilation or the supraglottic airway devices, the laryngeal mask and the laryngeal tube. the purpose of this study is to compare in anesthetised patients airway management and ventilation with bag-valve mask, laryngeal mask and laryngeal tube.

Eligibility criteria:
inclusion criteria: * asa i-ii -\> 18 years old * elective surgery in general anesthesia exclusion criteria: * patient not sober * bmi \> 35kg/m2 * pathologies of cerebral spine or peripheral neurological deficit * hiatus hernia, history of gastric reflux * stomach or esophagus -operation in the medical history * acute respiratory infection or obstructive lung disease * non elective surgery * facial deformity

Keywords: airway bag-valve -mask- ventilation laryngeal mask - ventilation laryngeal tube - ventilation
the effect of esmolol on patients with sepsis

Conditions: Sepsis

Summary: the investigators conduct an rct to explore the efficacy of esmolol in patients with septic shock and sepsis.

severe sepsis, septic shock, and their complications have become the major healthcare problem that affects millions of people each year, resulting in high mortality rates. septic responses have an extremely complex chain of events including inflammatory and anti-inflammatory processes, humoral and cellular reactions, and cardiocirculatory abnormalities. esmolol may have some potential in treating septic shock and sepsis. the investigators conduct an rct to explore the efficacy of esmolol in patients with septic shock and sepsis.

Eligibility criteria:
inclusion criteria: * sepsis patients * hr\>100bpm 6h after admission * with cvc and scvo2\>65% exclusion criteria: * age \<18 years, * used β-blocker before, * cardiac dysrhythmias, * need for an inotropic agent, * valvular heart disease, * hemoglobin\>6g/l * pregnancy.

Keywords: sepsis septic shock esmolol
bearing nspva embolization for uterine artery embolization (better-uae)

Conditions: Uterine Fibroid

Summary: this is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with bearing nspva embolization particles for uterine fibroid embolization. data collection will include safety and performance outcome relating to the use of bearing nspva, through 6 months.


Eligibility criteria:
inclusion criteria: * adult women ≥ 18 years old at the time of enrollment. * subject has symptomatic uterine fibroid(s), suitable to embolization. * subject provides written informed consent. exclusion criteria: * subject is pregnant. * subject has suspected pelvic inflammatory disease or any other pelvic infection. * subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).
a study evaluating the onset-of-action, safety, and efficacy of rdx227675 for the treatment of hyperkalemia

Conditions: Hyperkalemia

Summary: this phase 2, single-blind, placebo-controlled study will evaluate the onset-of-action, safety, and efficacy of rdx227675 for the treatment of hyperkalemia. subjects who qualify are randomized into one of four treatment groups: group 1 (placebo qd), group 2 (rdx227675 10 g qd), group 3 (rdx227675 20 g qd), group 4 (rdx227675 30 g qd).

the study consists of a screening visit, a 7-day treatment period, and a 7-day treatment-free follow-up period.

Eligibility criteria:
inclusion criteria: * 18 to 85 years old, inclusive * two consecutive i-stat k values ≥ 5.5 to \< 6.5 mmol/l, measured a minimum of 60-minutes apart within 1 day of first rdx227675 dose on day 1 (prior to randomization) * i-stat k value ≥ 5.5 to \< 6.5 mmol/l on day 1 (prior to randomization) * ability to have repeated blood draws or effective venous catheterization * females of child bearing potential must have negative urine pregnancy test on day 1 (prior to randomization) * females but be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods * males must agree to use an appropriate method of contraception or have documented surgical sterilization exclusion criteria: * pseudohyperkalemia signs and symptoms * treatment with k lowering drugs, within 7 days prior to randomization * uncontrolled type 2 diabetes, as defined as most recent historical hba1c \> 10%, or hospitalization to treat hyper- or hypo-glycemia in the past 3 months * diabetic ketoacidosis * known hypersensitivity to polystyrene sulfonate * significant cardiovascular or cerebrovascular events in the past 2 months * severe heart failure, defined as nyha (new york heart association) class iv or hospitalization to treat heart failure in previous 3 months * history of bowel obstruction, swallowing disorders, severe gastrointestinal disorders, or major gastrointestinal surgery * major psychiatric disorder (dsm-iii-r or dsm-iv) including major depression or other psychoses that has required hospitalization in the last 3 years. history of attempted suicide or uncontrolled bipolar disorder. * use of an investigational product within 30 days prior to screening
single-cell cbd biomarkers of inflammation reduction in people living with hiv

Conditions: Chronic Inflammation

Summary: people living with hiv (plwh) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing plwh. the investigators propose to study the effects of cbd on inflammation in plwh, and establish the molecular role of different immune cells in this process. the investigators plan to use single cell rna-sequencing (scrnaseq) to isolate cbd-specific cellular phenotypes from five persons with hiv who will provide blood samples before and after taking cbd.


Eligibility criteria:
inclusion criteria: * willingness to take cbd and to participate in follow up for two months * older than 21 and younger than 60 * under antiretroviral therapy for 5+ years and suppressed viral load (cd4 count \<350cells/ml) exclusion criteria: * conditions/medications that may impair the immune response, e.g., rheumatoid arthritis, cancer, diabetes, chronic infections, cad (cold agglutinin disease), cellulitis, autoimmune diseases such as lupus, sarcoidosis * all medications that may affect inflammation such as aspirin, steroids, statins; cd4 count \<350cells/ml), pregnancy, and current marijuana or cbd use (urine drug screen) * uf(university of florida)/shands staff and students will not be considered for enrollment
pharmacokinetics and relative bioavailability study

Conditions: Urinary Bladder, Overactive

Summary: a single-dose pharmacokinetics and relative bioavailability study of tolterodine from two microspheres in powder blend extended release formulations compared to the commercial extended release capsules

pharmacokinetics and relative bioavailability study of tolterodine from two microspheres in powder blend extended release formulations compared to the commercial extended release capsules

Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 21 and 55 years, inclusive exclusion criteria: * evidence or history of clinically significant diseases

Keywords: pharmacokinetics relative bioavailability tolterodine microspheres in powder blend overactive urinary bladder
reliability of consumer sleep trackers in patients suffering from obstructive sleep apnea syndrome

Conditions: Obstructive Sleep Apnea Syndrome

Summary: during last years, numerous sleep trackers have been commercialized. they are intended to give indications about sleep quality/duration in order to give people an internet-based feedback about their own sleep. for clinical and research purposes, tri-axial accelerometers/multi-sensors devices are used routinely to assess objective sleep quality/patterns. their use is also validated to estimate sleep in obstructive sleep apnea syndrome (osa). the purpose of the present study is to compare the accuracy of consumer-level sleep trackers and validated tools to measure sleep in osa patients.

during last years, numerous sleep trackers have been commercialized. they are working on accelerometer-based technology. they are intended to give indications about sleep quality/duration in order to give people an internet-based feedback about their own sleep.. for clinical and research purposes, tri-axial accelerometers/multi-sensors devices are used routinely to assess objective sleep quality/patterns. their use is also validated to estimate sleep in obstructive sleep apnea syndrome (osa). the purpose of our study is to compare the accuracy of consumer-level sleep trackers and validated tools to measure sleep in osa patients.

Eligibility criteria:
inclusion criteria: * high clinical suspicion of obstructive sleep apnea syndrome exclusion criteria: * other associated sleep disorder * inability to sign informed consent
comparing the clinical effects of posterior approach versus lateral approach in osteoarthritis patients with a tha

Conditions: Unilateral Primary Osteoarthritis of Hip

Summary: the aim of this study is to investigate the clinical outcome of the two different, but widely used, surgical approaches (posterior approach and lateral approach) of primary total hip arthroplasty in patients diagnosed with osteoarthritis. this study is divided into one main study and two sub-studies. the main study investigates the patient-reported outcome measures (questionnaire) within the first year post surgery. the two sub-studies investigate; i) the level of physical function and pain within the first 3 month after surgery, and ii) investigate the potential difference the two approaches have on gait-patterns and maximal isometric hip-muscle-strength, within the first year after surgery. both approaches are described with potential drawbacks. posterior approach has a higher risk of dislocation of the prostheses and revision due to dislocation compared with lateral approach. contrary, lateral approach is described with the potential drawbacks of pain, lower physical function, gait abnormalities and muscle weakness, leading to less satisfied patients. however, according to a cochrane analysis from 2004 concludes, more investigation is needed to determine the extent of differences.


Eligibility criteria:
inclusion criteria: * age: 45-70 years, both included. * patients schedule for primary cementless total hip arthroplasty. * endstage hip osteoarthritis(oa) or minor dysplasia of the hip(ce-angle \> 20 degrees). exclusion criteria: 1. more major joint (hip or knee) than the current hip affected with oa, with expected joint replacement surgery within a year. 2. prior joint replacement surgery on any major joint (hip, knee) in lower limb. 3. bmi above 35. 4. any physical disability that prevents patients from walking 20 meters without aid. 5. the patients is not suitable for standard cementless prosthetic components. 6. any neurological disease (ex. cerebral thrombosis, parkinson) compromising the walking ability. 7. any severe medical condition compromising walking ability (ex. chronic heart failure, chronic obstructive pulmonary disease). 8. severe dementia. 9. inability to read and understand danish writing and oral instructions. 10. do not want to participate

Keywords: controlled clinical trial operative surgical procedures treatment outcome pain measurement quality of life questionnaires/standards activities of daily living biomechanics gait* hip joint/physiology* hip joint/surgery* recovery of function/physiology